Partner Dan Shores and Associate Michael Ellenberger will lead a roundtable on "AI in Biopharmaceutical Licensing" at the Licensing Executives Society (LES) USA-Canada 2025 Annual Meeting taking place October 19-22, 2025, in Boston, Massachusetts. Dan and Michael's roundtable will take place on Monday, October 20.
Artificial intelligence (AI) is progressively playing a pivotal role in transforming the biopharmaceutical landscape, influencing every stage from drug development to discovery and commercialization. As the USPTO and FDA issue new guidance related to AI-developed drugs, and the industry undergoes related technological advancements, licensing deals have evolved to address the new challenges caused by this rapid growth. In this interactive roundtable session, we will delve into this dynamic including the key considerations for how companies can effectively leverage and in-license this technology in an array of deals.
Dan and Michael's session will be a collaborative discussion, where attendees will have the opportunity to share their own experiences, insights, and challenges with AI in their licensing practices.
Licensing Executive Society USA & Canada (LES) is the original, leading professional society for intellectual property and licensing experts.
To learn more about the event, and to register, please visit the LES USA-Canada 2025 Annual Meeting webpage.
